• Home
  •  / Seattle Genetics

Seattle Genetics

OverviewSuggest Edit

Seattle Genetics is a biotechnology company that is focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Its antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.
The Company also is advancing a deep pipeline of innovative therapies for blood cancers and solid tumors, including vadastuximab talirine (SGN-CD33A) an ADC in the pivotal phase 3 CASCADE clinical trial for acute myeloid leukemia (AML), enfortumab vedotin (ASG-22ME) for urothelial cancer under its collaboration with Astellas, and SGN-LIV1A for triple-negative breast cancer. Its programs are designed to address significant unmet medical needs and to improve treatment outcomes for patients.

TypePublic
Founded1998
HQBothell, USMap
Websiteseattlegenetics.com
Employee Ratings4.2More
Overall CultureA+More
View Jobs (268)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)1,605(+24%)
Job Openings268
Revenue (FY, 2019)$916.7 M(+41%)
Share Price (Nov 2020)$168.8 (-1%)
Cybersecurity ratingAMore

Key People/Management at Seattle Genetics

Clay Siegall

Clay Siegall

President, Chief Executive Officer and Chairman of the Board
Roger Dansey

Roger Dansey

Chief Medical Officer
Vaughn Himes

Vaughn Himes

Chief Technical Officer
Todd Simpson

Todd Simpson

Chief Financial Officer
Jean Liu

Jean Liu

General Counsel and Executive Vice President, Legal Affairs
Christopher Pawlowicz

Christopher Pawlowicz

Executive Vice President, Human Resources
Show more

Seattle Genetics Office Locations

Seattle Genetics has offices in Bothell and Zug
Bothell, US (HQ)
21717 30th Dr SE Building 3
Bothell, US
21823 30th Dr SE
Zug, CH
19 Dammstrasse, Suite 403–406
Show all (3)

Seattle Genetics Financials and Metrics

Seattle Genetics Revenue

Seattle Genetics's revenue was reported to be $916.71 m in FY, 2019
USD

Revenue (Q3, 2020)

267.5m

Market capitalization (12-Nov-2020)

30.2b

Closing stock price (12-Nov-2020)

168.8

Cash (30-Sept-2020)

919.5m

EV

29.4b
Seattle Genetics's current market capitalization is $30.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

94.8m210.8m269.3m286.8m336.8m418.1m482.3m654.7m916.7m

Revenue growth, %

6%17%24%

Cost of goods sold

3.1m11.5m13.8m17.5m24.5m28.2m34.8m

Gross profit

91.7m199.3m255.5m269.2m312.3m390.0m447.5m
Quarterly
USDQ1, 2011Q2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

48.2m34.7m33.7m57.3m73.6m71.0m68.3m68.3m75.9m82.2m77.1m84.1m111.2m95.4m106.3m109.1m108.2m135.3m140.6m170.2m169.4m195.2m218.4m213.3m234.5m240.5m267.5m

Cost of goods sold

3.1m3.0m2.7m3.2m3.3m3.5m3.7m4.1m4.7m5.2m5.9m6.6m5.9m6.9m7.4m7.5m8.1m9.0m10.4m48.2m

Gross profit

45.2m31.7m30.9m54.2m70.2m67.4m64.6m64.2m71.1m76.9m71.2m77.4m105.2m88.5m98.9m101.7m100.2m126.3m130.2m192.2m

Gross profit Margin, %

94%91%92%94%95%95%95%94%94%94%92%92%95%93%93%93%93%93%93%80%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

87.6m54.7m64.1m56.9m102.3m108.7m160.9m78.2m274.6m

Accounts Receivable

55.0m33.4m29.5m39.2m52.9m61.9m84.8m146.3m236.0m

Prepaid Expenses

3.8m4.5m5.8m11.9m11.5m19.1m43.4m43.7m

Inventories

9.5m849.0k27.1m43.5m57.0m68.1m60.0m53.2m85.9m
Quarterly
USDQ1, 2011Q2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

61.5m79.8m53.3m60.8m54.9m34.9m27.6m119.5m44.8m38.8m50.2m62.6m79.0m614.1m119.5m192.1m131.0m75.8m197.1m128.1m186.9m159.3m115.5m84.3m64.1m193.5m249.1m117.3m919.5m

Accounts Receivable

8.6m11.0m56.6m31.6m35.2m44.7m47.7m29.2m37.9m34.9m43.8m49.6m45.3m63.5m52.4m57.7m65.1m73.7m71.9m90.4m118.6m150.0m152.5m157.0m182.3m190.3m224.6m290.1m293.4m

Prepaid Expenses

4.4m5.3m6.6m4.7m7.2m6.3m5.7m7.1m8.4m8.3m8.2m11.8m8.3m14.2m12.2m15.7m15.4m22.4m18.9m44.1m36.9m26.2m37.3m40.4m43.7m52.0m54.8m57.5m

Inventories

15.8m25.7m429.0k1.1m1.2m26.0m29.0m30.5m37.5m43.1m47.5m44.5m60.1m71.7m71.6m60.7m69.2m60.8m71.9m70.9m75.2m67.2m73.2m92.0m84.7m90.0m96.7m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(152.0m)(53.8m)(62.5m)(76.1m)(120.5m)(140.1m)(125.5m)(222.7m)(158.6m)

Depreciation and Amortization

4.2m6.2m8.6m12.5m14.5m18.0m24.3m26.0m23.8m

Inventories

(9.5m)(28.3m)10.7m(16.4m)(13.5m)(11.2m)8.1m6.7m(32.7m)

Accounts Payable

27.3m3.1m1.5m18.4m6.5m29.9m19.1m33.1m
Quarterly
USDQ1, 2011Q2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(32.7m)(84.2m)(12.3m)(29.5m)(43.2m)(16.3m)(23.2m)(46.8m)(16.3m)(33.9m)(49.5m)(21.7m)(69.2m)(95.6m)(20.5m)(53.2m)(85.0m)(60.0m)(116.3m)(66.3m)(111.7m)(35.4m)(102.9m)(13.3m)(92.6m)(184.5m)(168.4m)(189.6m)446.6m

Depreciation and Amortization

875.0k1.8m1.5m3.0m4.6m1.7m3.8m6.1m2.8m5.9m9.1m3.4m7.0m10.8m4.2m8.6m13.3m4.8m10.2m16.4m7.0m13.8m19.0m4.9m9.9m14.1m6.0m16.6m36.8m

Inventories

(6.3m)(16.2m)(24.8m)4.0m(914.0k)11.7m(2.0m)(3.4m)(10.5m)382.0k(4.0m)(1.1m)(3.1m)(14.7m)(14.7m)7.4m(1.1m)7.3m(11.9m)(11.0m)(15.2m)(14.0m)(19.9m)(38.8m)1.2m(4.1m)(10.8m)

Accounts Payable

(390.0k)8.1m(12.5m)(894.0k)(10.5m)(10.4m)(6.6m)(2.7m)(521.0k)3.4m10.1m3.1m9.1m(633.0k)(1.6m)6.5m8.4m(18.5m)(11.1m)6.2m(28.9m)(10.0m)2.2m
show all
USDQ1, 2011

Financial Leverage

1.6 x
Show all financial metrics

Seattle Genetics Acquisitions / Subsidiaries

Company NameDateDeal Size
Cascadian TherapeuticsJanuary 31, 2018$614 m

Seattle Genetics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

Learn more about our premium products
SecurityScorecard logo

Seattle Genetics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Seattle Genetics Online and Social Media Presence

Seattle Genetics's Trends

Embed Graph

Seattle Genetics Company Culture

  • Overall Culture

    A+

    91/100

  • CEO Rating

    A+

    94/100

  • Compensation

    A+

    93/100

Learn more on Comparably

Seattle Genetics Blogs

July 26, 2019

Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 26, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the completion of its previously announced underwritten public offering of 8,214,286 shares of its common stock at a price to the public of $70.00 per share, including 1,071,428 shares sold
July 24, 2019

Seattle Genetics Announces Pricing of Public Offering of Common Stock

Seattle Genetics Announces Pricing of Public Offering of Common Stock Content Import Tue, 07/23/2019 - 22:26 Seattle Genetics Announces Pricing of Public Offering of Common Stock July 23, 2019 at 10:26 PM EDT This release is a backfill from a News Wire …
July 23, 2019

Seattle Genetics Announces Proposed Public Offering of Common Stock

Seattle Genetics Announces Proposed Public Offering of Common Stock Content Import Tue, 07/23/2019 - 16:09 Seattle Genetics Announces Proposed Public Offering of Common Stock July 23, 2019 at 4:09 PM EDT This release is a backfill from a News Wire …
July 16, 2019

Seattle Genetics Reports Second Quarter 2019 Financial Results

Seattle Genetics Reports Second Quarter 2019 Financial Results Content Import Tue, 07/16/2019 - 16:03 Seattle Genetics Reports Second Quarter 2019 Financial Results July 16, 2019 at 4:02 PM EDT This release is a backfill from a News Wire Earning…
July 16, 2019

Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer Content Import Tue, 07/16/2019 - 08:01 Seattle Genetics and Astellas Announce Submission of Biologics License …
July 02, 2019

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019

BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 2, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets. Following the announcement, management will host a conference call and
Show more

 Seattle Genetics Frequently Asked Questions

  • When was Seattle Genetics founded?

    Seattle Genetics was founded in 1998.

  • Who are Seattle Genetics key executives?

    Seattle Genetics's key executives are Clay Siegall, Roger Dansey and Vaughn Himes.

  • How many employees does Seattle Genetics have?

    Seattle Genetics has 1,605 employees.

  • What is Seattle Genetics revenue?

    Latest Seattle Genetics annual revenue is $916.7 m.

  • What is Seattle Genetics revenue per employee?

    Latest Seattle Genetics revenue per employee is $571.2 k.

  • Who are Seattle Genetics competitors?

    Competitors of Seattle Genetics include Immunomedics, Ectin Research and Antikor.

  • Where is Seattle Genetics headquarters?

    Seattle Genetics headquarters is located at 21717 30th Dr SE Building 3, Bothell.

  • Where are Seattle Genetics offices?

    Seattle Genetics has offices in Bothell and Zug.

  • How many offices does Seattle Genetics have?

    Seattle Genetics has 3 offices.